Table 2.
Patient characteristics across activity clusters
| Activity Level | PHANTOM |
Penn Cohort |
||||||
|---|---|---|---|---|---|---|---|---|
| Low (n = 13) | Medium (n = 23) | High (n = 19) | P Value | Low (n = 25) | Medium (n = 13) | High (n = 19) | P Value | |
| Age, yr | 66 ± 7 | 63 ± 9 | 54 ± 11 | <0.001 | 48 ± 16 | 52 ± 23 | 48 ± 16 | 0.77 |
| Sex, female, % | 85 | 74 | 58 | 0.24 | — | — | — | — |
| Body mass index, kg/m2 | 29 ± 6 | 31 ± 7 | 29 ± 5 | 0.42 | 28 ± 6 | 27.5 ± 8 | 27.2 ± 4 | 0.89 |
| PAH etiology, % | 0.09 | 0.73 | ||||||
| Idiopathic/heritable | 15 | 57 | 63 | — | 48 | 38 | 58 | — |
| Connective tissue disease | 39 | 22 | 16 | — | 28 | 39 | 32 | — |
| Other | 46 | 21 | 21 | — | 24 | 23 | 10 | — |
| PAH medications, % | 0.17 | 0.07 | ||||||
| Only oral | 69 | 65 | 68 | — | 48 | 62 | 63 | — |
| Inhaled ± oral | 8 | 22 | 0 | — | 4 | 30 | 0 | — |
| Parenteral prostacyclin analog ± oral | 23 | 13 | 32 | — | 48 | 8 | 37 | — |
| WHO functional class, % | 0.008 | 0.26 | ||||||
| I | 0 | 0 | 21 | — | 0 | 15 | 16 | — |
| II | 54 | 61 | 74 | — | 48 | 54 | 37 | — |
| III | 46 | 39 | 5 | — | 52 | 31 | 47 | — |
Definition of abbreviations: PAH = pulmonary arterial hypertension; Penn = Pennsylvania; PHANTOM = Pulmonary Hypertension and Anastrozole; WHO = World Health Organization.
Low, medium, and high indicate activity levels. Data are summarized as n % or median (interquartile range).